Cargando…
Treatment of diabetic kidney disease: current and future targets
Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease in Korea and worldwide, and is a risk factor for the development of cardiovascular complications. The conventional treatments for DKD are control of blood glucose and blood pressure levels by inhibiting the renin-angiotensin...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511942/ https://www.ncbi.nlm.nih.gov/pubmed/28704915 http://dx.doi.org/10.3904/kjim.2016.219 |
_version_ | 1783250422962585600 |
---|---|
author | Kim, Mi-Kyung |
author_facet | Kim, Mi-Kyung |
author_sort | Kim, Mi-Kyung |
collection | PubMed |
description | Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease in Korea and worldwide, and is a risk factor for the development of cardiovascular complications. The conventional treatments for DKD are control of blood glucose and blood pressure levels by inhibiting the renin-angiotensin system. However, the prevalence of DKD continues to increase and additional therapies are required to prevent or ameliorate the condition. Many drugs have been, or are being, developed to target the molecular mechanisms in play in DKD. This review focuses on DVD treatment, considering current and emerging therapeutic targets and the clinical trial-based evidence. |
format | Online Article Text |
id | pubmed-5511942 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The Korean Association of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-55119422017-07-17 Treatment of diabetic kidney disease: current and future targets Kim, Mi-Kyung Korean J Intern Med Review Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease in Korea and worldwide, and is a risk factor for the development of cardiovascular complications. The conventional treatments for DKD are control of blood glucose and blood pressure levels by inhibiting the renin-angiotensin system. However, the prevalence of DKD continues to increase and additional therapies are required to prevent or ameliorate the condition. Many drugs have been, or are being, developed to target the molecular mechanisms in play in DKD. This review focuses on DVD treatment, considering current and emerging therapeutic targets and the clinical trial-based evidence. The Korean Association of Internal Medicine 2017-07 2017-06-30 /pmc/articles/PMC5511942/ /pubmed/28704915 http://dx.doi.org/10.3904/kjim.2016.219 Text en Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Kim, Mi-Kyung Treatment of diabetic kidney disease: current and future targets |
title | Treatment of diabetic kidney disease: current and future targets |
title_full | Treatment of diabetic kidney disease: current and future targets |
title_fullStr | Treatment of diabetic kidney disease: current and future targets |
title_full_unstemmed | Treatment of diabetic kidney disease: current and future targets |
title_short | Treatment of diabetic kidney disease: current and future targets |
title_sort | treatment of diabetic kidney disease: current and future targets |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511942/ https://www.ncbi.nlm.nih.gov/pubmed/28704915 http://dx.doi.org/10.3904/kjim.2016.219 |
work_keys_str_mv | AT kimmikyung treatmentofdiabetickidneydiseasecurrentandfuturetargets |